Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1317-1327

  Hamrén, Bengt ^a   Öhman, K Peter ^b   Svensson, Maria K ^c   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

peroxisome proliferator activated receptor (PPAR); pharmacokinetics pharmacodynamics (PK PD); renal function; Tesaglitazar

Indexed keywords

TESAGLITAZAR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT WITHDRAWAL;

AGED; ALKANESULFONATES; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENYLPROPIONATES; THIAZOLIDINEDIONES;

EID: 84866031914     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011416937     Document Type: Article

References (35)

1. Bays H, McElhattan J, Bryzinski BS. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2007 ; 4 (3). 181-193
2. Goke B, Gause-Nilsson I, Persson A. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab Vasc Dis Res. 2007 ; 4 (3). 204-213
3. Ratner RE, Parikh S, Tou C. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. Diab Vasc Dis Res. 2007 ; 4 (3). 214-221
4. Wilding JP, Gause-Nilsson I, Persson A. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res. 2007 ; 4 (3). 194-203
5. AstraZeneca. A 24-week, randomised, parallel-group, multi-centre, active-controlled (pioglitazone) study of the renal effects of tesaglitazar in patients with type 2 diabetes mellitus: ARMOR (Analysing Renal Mechanisms of Creatinine Excretion in Patients on Tesaglitazar). Available at: http://www.astrazenecaclinicaltrials.com/search/?itemId=8543735. Accessed December 1, 2010.
6. Owens DR. Thiazolidinediones: a pharmacological overview. Clin Drug Investig. 2002 ; 22 (8). 485-505
7. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004 ; 53 (suppl 1). S43 - S50
8. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 ; 98 (19). 2088-2093
9. Ericsson H, Hamren B, Bergstrand S, et al. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator- activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab Dispos. 2004 ; 32 (9). 923-929
10. Ottosson P, Ericsson H, Lagerström P, Samuelsson S, Gause-Nilsson I, Samuelsson O. Pharmacokinetics of tesaglitazar, a dual PPAR alpha/gamma agonist, in subjects with different degrees of renal insufficiency. J Am Soc. 2010 ; 17:
11. Hamren B, Ericsson H, Samuelsson O, Karlsson MO. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function: evidence of interconversion. Br J Clin Pharmacol. 2008 ; 65 (6). 855-863
12. Fagerberg B, Edwards S, Halmos T, et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia. 2005 ; 48 (9). 1716-1725
13. Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr Med Res Opin. 2006 ; 22 (12). 2575-2590
14. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009 ; 374 (9684). 126-135
15. Herz M, Gaspari F, Perico N, et al. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol.:
16. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 ; 366 (9500). 1849-1861
17. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003 ; 139 (2). 137-147
18. Svennberg H, Bergh S, Stenhoff H. Factorial design for the development of automated solid-phase extraction in the 96-well format for determination of tesaglitazar, in plasma, by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 ; 787 (2). 231-241
19. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993 ; 21 (4). 457-478
20. Beal SL, Sheiner LB, Boeckman AJ NONMEM Users Guides (1989-2006). Ellicott City, Md: Icon Development Solutions ; 2010:
21. Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 ; 58 (1). 51-64
22. NONMEM Users Guide VII (1989-2006). Beal SL Sheiner LB Boeckman AJ, ed. Ellicott City, Md: Icon Development Solutions ; 2010:
23. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001 ; 28 (3). 231-252
24. Hamren B, Bjork E, Sunzel M, Karlsson M. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther. 2008 ; 84 (2). 228-235
25. Beck LH. Changes in renal function with aging. Clin Geriatr Med. 1998 ; 14 (2). 199-209
26. Hamren B, Ericsson H, Öhman P, Anzalone D, Karlsson MO. A pooled population pharmacokinetic analysis of tesaglitazar in patients with type 2 diabetes or with manifestation of insulin resistance. ISSN 1871-6032. Abstract of the Annual Meeting of the Population Approach Group Europe (PAGE) ; ;..
27. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976 ; 16 (1). 31-41
28. Chen YJ, Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J Pharmacol Exp Ther. 2008 ; 324 (2). 658-663
29. Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol. 2002 ; 57 (5). 407-408
30. Wilson MW, Lay LT, Chow CK, Tai HH, Robertson LW, Glauert HP. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch Toxicol. 1995 ; 69 (7). 491-497
31. Efrati S, Berman S, Ilgiyeav E, Averbukh Z, Weissgarten J. PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron Exp Nephrol. 2007 ; 106 (4). e107 - e112
32. Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure. Pharmacol Res. 2006 ; 54 (3). 234-240
33. Cha DR, Zhang X, Zhang Y, et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes. 2007 ; 56 (8). 2036-2045
34. Okada T, Wada J, Hida K, et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes. 2006 ; 55 (6). 1666-1677
35. Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy: relevance to renoprotection. Nat Clin Pract Nephrol. 2005 ; 1 (1). 33-43